191103-80-7Relevant articles and documents
Intermediate for preparing medetomidine and its preparation method and use
-
Paragraph 0094-0096, (2018/08/03)
The invention provides an intermediate for preparing medetomidine. The intermediate is a compound shown in the formula (I). The invention also provides a preparation method of the intermediate, and ause of the intermediate in the preparation of medetomidine. The compound shown in the formula (I) is used for preparation of medetomidine so that the raw material is cheap and easy to obtain, synthesis processes are simple, the reaction cycle is short, the environmental pollution is avoided, operation is simple, the harsh reaction conditions are avoided, the operation and post-treatment are simple, the yield and the product purity are high, the intermediate in each step is a solid and is easy to purify, a production cost is low, and the intermediate is suitable for industrial large-scale production and conforms to the principle of green chemistry.
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase
Chong, Pek,Sebahar, Paul,Youngman, Michael,Garrido, Dulce,Zhang, Huichang,Stewart, Eugene L.,Nolte, Robert T.,Wang, Liping,Ferris, Robert G.,Edelstein, Mark,Weaver, Kurt,Mathis, Amanda,Peat, Andrew
supporting information, p. 10601 - 10609 (2013/02/23)
A new series of non-nucleoside reverse transcriptase inhibitors based on an imidazole-amide biarylether scaffold has been identified and shown to possess potent antiviral activity against HIV-1, including the NNRTI-resistant Y188L mutated virus. X-ray crystallography of inhibitors bound to reverse transcriptase, including a structure of the Y188L RT protein, was used extensively to help identify and optimize the key hydrogen-bonding motif. This led directly to the design of compound 43 that exhibits remarkable antiviral activity (EC50 1 nM) against a wide range of NNRTI-resistant viruses and a favorable pharmacokinetic profile across multiple species.
THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER
-
Page/Page column 29-30, (2010/11/05)
The present invention encompasses compounds of general formula (1) wherein 5 R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and th